SCHEMBL12430971

SCHEMBL12430971

Cc1cc(Nc2cc(C)[nH]n2)nc(COc2ccc(Cl)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 7/20 0.48
PIK3C3 Q8NEB9 3/20 0.47
GSK3B P49841 1/20 0.43
AURKA O14965 4/20 0.42
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP3A4 P08684 3/20 0.41
CYP1A2 P05177 2/20 0.41
PLK4 O00444 1/20 0.41
PAK4 O96013 1/20 0.41
NTRK1 P04629 1/20 0.41
RAB29 O14966 1/20 0.41
FYN P06241 1/20 0.41
YES1 P07947 1/20 0.41
LYN P07948 1/20 0.41
FGFR1 P11362 1/20 0.41
CYP2C9 P11712 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13609109 0.91 PIK3C3 (0.48) RETPIK3C3AURKACYP3A4CYP1A2
SCHEMBL12430972 0.87 PIK3C3 (0.41) RETPIK3C3GSK3BAURKAMEN1
SCHEMBL12430970 0.85 MAPT (0.44) MEN1HTTKMT2A
SCHEMBL5593383 0.85 CYP1A2 (0.42) HTTHSD17B10CYP3A4CYP1A2CYP2C19
SCHEMBL12430973 0.82 IGF1R (0.49) RETMEN1HTTKMT2ACYP3A4
SCHEMBL13054918 0.80 PIK3C3 (0.44) RETPIK3C3GSK3BAURKACYP3A4
SCHEMBL12430767 0.77 IGF1R (0.50) PIK3C3GSK3BAURKAMEN1HTT
SCHEMBL12430967 0.76 AURKA (0.43) RETAURKACYP3A4CYP1A2PLK4
SCHEMBL12430765 0.76 IGF1R (0.52) GSK3BAURKAMEN1HTTKMT2A
SCHEMBL12430966 0.76 AURKA (0.48) RETGSK3BAURKACYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA RET 277/4885PIK3C3 322/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.